{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:52Z","timestamp":1787009032653,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Science and Technology Project of Henan Province","doi-asserted-by":"publisher","award":["252102310077"],"award-info":[{"award-number":["252102310077"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Scientific Research Project of Zhengzhou City","award":["ZZYK2024050"],"award-info":[{"award-number":["ZZYK2024050"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Following with the widespread adoption of antiretroviral treatment (ART) for human immunodeficiency virus type 1 (HIV-1), the prevalence of transmitted drug resistance (TDR) among newly diagnosed people living HIV-1 (PLWH) has shown an upward trend. Thus, a close monitoring of TDR can provide valuable data for local management of PLWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Plasma samples were collected from newly diagnosed PLWH seeking treatments in the Sixth People\u2019s Hospital of Zhengzhou from Jan 2024 to December 2024. The partial pol and the complete integrase gene coding sequences were separately amplified, sequenced, and analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of a total of 1249 patients, we obtained partial pol sequences from 1227 patients and integrase sequences from 1224 patients. Subtyping analysis showed predominance of CRF07_BC (41.73%, 512\/1227), followed by CRF01_AE (27.06%, 332\/1227), B (21.35%, 262\/1227), CRF55_01B (4.81%, 59\/1227), and CRF08_BC (1.96%, 24\/1227). Transmitted drug resistance mutations were detected in 137 patients, giving a TDR prevalence of 11.25% (137\/1227). The most frequently detected mutations leading to low-level or above drug resistance against nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase transfer inhibitors were M184I\/V, K103N\/S, M46I\/L\/V, and E138A, respectively. The prevalence of TDR remained at a modest level and showed no significant difference when compared with previous years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genotypic drug resistance testing is recommended for newly diagnosed PLWH before the initiation of ART to provide effective treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf255","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:20:38Z","timestamp":1752729638000},"page":"2496-2502","source":"Crossref","is-referenced-by-count":1,"title":["Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-5638","authenticated-orcid":false,"given":"Jinjin","family":"Liu","sequence":"first","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Deng","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Hou","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Wei","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7543-3132","authenticated-orcid":false,"given":"Yuqi","family":"Huo","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou) , Translational Medicine Research Center, Zhengzhou 450000 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2025090219522657500_dkaf255-B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jiac.2016.10.002","article-title":"Current status of HIV\/AIDS in the ART era","volume":"23","author":"Yoshimura","year":"2017","journal-title":"J Infect Chemother"},{"key":"2025090219522657500_dkaf255-B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025090219522657500_dkaf255-B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antiviral Res"},{"key":"2025090219522657500_dkaf255-B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jama.1997.03540260059037","article-title":"HIV-1 protease inhibitors. A review for clinicians","volume":"277","author":"Deeks","year":"1997","journal-title":"JAMA"},{"key":"2025090219522657500_dkaf255-B5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"2025090219522657500_dkaf255-B6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.coviro.2011.10.020","article-title":"Drug resistance in HIV-1","volume":"1","author":"Kuritzkes","year":"2011","journal-title":"Curr Opin Virol"},{"key":"2025090219522657500_dkaf255-B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11904-019-00478-x","article-title":"Optimizing treatment for adults with HIV\/AIDS in China: successes over two decades and remaining challenges","volume":"17","author":"Cao","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025090219522657500_dkaf255-B8","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.eclinm.2024.102859","article-title":"Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis","volume":"77","author":"Ge","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025090219522657500_dkaf255-B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/187152611795589663","article-title":"HIV treatment adherence, drug resistance, virologic failure: evolving concepts","volume":"11","author":"Nachega","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"2025090219522657500_dkaf255-B10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy","volume":"191","author":"Harrigan","year":"2005","journal-title":"J Infect Dis"},{"key":"2025090219522657500_dkaf255-B11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00705-020-04606-6","article-title":"Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017\u20132019)","volume":"165","author":"Yang","year":"2020","journal-title":"Arch Virol"},{"key":"2025090219522657500_dkaf255-B12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s15010-021-01668-9","article-title":"Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018\u20132020)","volume":"49","author":"Yang","year":"2021","journal-title":"Infection"},{"key":"2025090219522657500_dkaf255-B13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12879-022-07576-z","article-title":"Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025090219522657500_dkaf255-B14","doi-asserted-by":"publisher","first-page":"2278254","DOI":"10.1080\/21505594.2023.2278254","article-title":"Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China","volume":"14","author":"Zhang","year":"2023","journal-title":"Virulence"},{"key":"2025090219522657500_dkaf255-B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hiv.13253","article-title":"Pretreatment drug resistance in people living with HIV: a large retrospective cohort study in Chongqing, China","volume":"23","author":"Liu","year":"2022","journal-title":"HIV Med"},{"key":"2025090219522657500_dkaf255-B16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025090219522657500_dkaf255-B17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"Wensing","year":"2025","journal-title":"J Infect Dis"},{"key":"2025090219522657500_dkaf255-B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12981-015-0043-1","article-title":"Transmitted drug resistance in recently infected HIV-positive individuals from four urban locations across Asia (2007\u20132010) TASER-S","volume":"12","author":"Jiamsakul","year":"2015","journal-title":"AIDS Res Ther"},{"key":"2025090219522657500_dkaf255-B19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.cr.7290354","article-title":"The HIV epidemic in China: history, response, and challenge","volume":"15","author":"He","year":"2005","journal-title":"Cell Res"},{"key":"2025090219522657500_dkaf255-B20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.46234\/ccdcw2023.129","article-title":"Changes in HIV-1 subtypes\/sub-subtypes, and transmitted drug resistance among ART-naive HIV-infected individuals\u2014China, 2004\u20132022","volume":"5","author":"Liu","year":"2023","journal-title":"China CDC Wkly"},{"key":"2025090219522657500_dkaf255-B21","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/pathogens11111321","article-title":"Drug resistance to integrase strand-transfer inhibitors among HIV-1-infected adults in Guangdong, China","volume":"11","author":"Lan","year":"2022","journal-title":"Pathogens"},{"key":"2025090219522657500_dkaf255-B22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1089\/aid.2020.0261","article-title":"Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons","volume":"37","author":"Bailey","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025090219522657500_dkaf255-B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study","volume":"31","author":"Santoro","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2025090219522657500_dkaf255-B24","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre","year":"2015","journal-title":"AIDS Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2496\/63780555\/dkaf255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2496\/63780555\/dkaf255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:52:36Z","timestamp":1756857156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/9\/2496\/8203700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,17]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf255","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]}}}